Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?

被引:39
作者
Evora, PRB [1 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Sch Med, Div Expt Surg,Dept Surg, UNAERP Med Sch,Heart Hosp Ribeirao Preto, BR-14015120 Ribeirao Preto, SP, Brazil
关键词
D O I
10.1016/S0022-5223(00)70152-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:632 / 633
页数:2
相关论文
共 6 条
[1]  
Andrade JCS, 1996, REV BRAS CIR CARDIOV, V11, P107
[2]  
Evora PRB, 1997, ANN EMERG MED, V30, P240
[3]  
EVORA PRB, 1997, ANN THORAC SURG, V63, P12
[4]   Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass [J].
Myles, PS ;
Leong, CK ;
Currey, J .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (05) :571-574
[5]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS INCREASE VASOCONSTRICTOR REQUIREMENTS AFTER CARDIOPULMONARY BYPASS [J].
TUMAN, KJ ;
MCCARTHY, RJ ;
OCONNOR, CJ ;
HOLM, WE ;
IVANKOVICH, AD .
ANESTHESIA AND ANALGESIA, 1995, 80 (03) :473-479
[6]   Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery [J].
Yiu, P ;
Robin, J ;
Pattison, CW .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (01) :195-196